Patents by Inventor Dayang Wu

Dayang Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to OX-2/CD200 and uses thereof
    Patent number: 9000133
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: April 7, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Antibodies to OX-2/CD200 and uses thereof
    Patent number: 8709415
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: April 29, 2014
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Hybrid antibodies
    Patent number: 8282924
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: October 9, 2012
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Dayang Wu
  • ANTIBODIES TO OX-2/CD200 AND USES THEREOF
    Publication number: 20120148579
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Application
    Filed: December 6, 2011
    Publication date: June 14, 2012
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Antibodies to OX-2/CD200 and uses thereof
    Patent number: 8075884
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: December 13, 2011
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Hybrid antibodies
    Patent number: 8067167
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: November 29, 2011
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Dayang Wu
  • HYBRID ANTIBODIES
    Publication number: 20110230646
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs.
    Type: Application
    Filed: April 18, 2011
    Publication date: September 22, 2011
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Russell Rother, Dayang Wu
  • Hybrid antibodies
    Patent number: 7927817
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: April 19, 2011
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Dayang Wu
  • HYBRID ANTIBODIES
    Publication number: 20110021758
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Application
    Filed: September 17, 2010
    Publication date: January 27, 2011
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Russell Rother, Dayang Wu
  • Antibodies to Ox-2/Cd200 and Uses Thereof
    Publication number: 20100285030
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Application
    Filed: January 11, 2007
    Publication date: November 11, 2010
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Hybrid antibodies
    Publication number: 20100076177
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Application
    Filed: June 30, 2008
    Publication date: March 25, 2010
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Russell Rother, Dayang Wu
  • Hybrid antibodies
    Patent number: 7399594
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: July 15, 2008
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Dayang Wu
  • Hybrid antibodies
    Patent number: 7393648
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: July 1, 2008
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell Rother, Dayang Wu
  • De-Immunized Anti-Cd3 Antibody
    Publication number: 20070292416
    Abstract: Antibodies or functional antibody fragments that recognize or interfere with the production of a component of the CD3 antigen complex are de-immunized.
    Type: Application
    Filed: May 28, 2004
    Publication date: December 20, 2007
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Russell Rother, Susan McKnight, Dayang Wu, Francis Carr, Anita Hamilton
  • Antibodies and fusion proteins that include engineered constant regions
    Publication number: 20070041972
    Abstract: Antibodies and/or fusion proteins contain a region that includes an IgG2-derived portion IgG4-derived portion.
    Type: Application
    Filed: May 28, 2004
    Publication date: February 22, 2007
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Russell Rother, Dayang Wu, Stephen Squinto, Mark Evans, Susan McKnight
  • Hybrid antibodies
    Publication number: 20040038308
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Application
    Filed: June 3, 2003
    Publication date: February 26, 2004
    Inventors: Russell Rother, Dayang Wu
  • Hybrid antibodies
    Publication number: 20030219861
    Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
    Type: Application
    Filed: December 3, 2002
    Publication date: November 27, 2003
    Inventors: Russell P. Rother, Dayang Wu